Trials & R&D · first seen 10h ago, updated 10h ago
N-of-1 therapies to address rare diseases with no commercial interest
Despite considerable advances in diagnosis, new gene-modifying modalities and significant regulatory inducements, there remains a long tail of rare diseases that are below the threshold required for sustainable commercial investment.
Summary from BioWorld Articles.
Coverage 1 article · 1 outlet
-
BioWorld ArticlesN-of-1 therapies to address rare diseases with no commercial interest